抄録
The prognosis of patients with Burkitt's lymphoma in Japan is usually poor, compared with that of the American and European cases, and the median survival period of the patients with “Stage IV” has been reported to be 2.3 months. Three cases of Burkitt's lymphoma (Stage IV) were treated with allogeneic bone marrow transplantation following a high dose chemoradiotherapy during their remission (2 in the 1st and 1 in the 2nd remission).
All were conditioned with cyclophosphamide (60 mg/kg/day) in day -5 and -4 and total body irradiation (10-12Gy) in day-2 and -1 and one received additional cytosine arabinoside and cerebrospinal and local irradiation. Two were grafted from HLA compatible siblings and another was from a DR-incompatible sibling. Engraftment was confirmed in all cases. One patient transplanted during 2nd CR died of relapse on the 160th day after the BMT. Remaining two cases, transplanted in their first remission, survived for more than 12 and 60 mos after the BMT without a recurrence of the disease. Allogeneic bone marrow transplantation for the treatment of Burkitt's lymphoma (Stage IV) might be a curative procedure, if it is performed in the 1st CR.
